TANDEM DIABETES CARE Business Summary

Tandem Diabetes Care (TNDM) operates a specialized medical device business model focused on the development and commercialization of automated insulin delivery (AID) systems. The company generates revenue through two primary segments: durable insulin pump hardware, including the flagship t:slim X2 and the smartphone-controlled Tandem Mobi, and a high-volume recurring stream of disposable supplies such as cartridges and infusion sets. In 2026, Tandem is executing a strategic pivot toward a "pay-as-you-go" (PayGo) reimbursement structure and expanding its pharmacy channel footprint to enhance patient accessibility and long-term revenue predictability. Within the competitive landscape, Tandem maintains a top-three global market position alongside Medtronic, Insulet Corporation, and Beta Bionics, differentiating itself through its industry-leading Control-IQ predictive algorithm and interoperability with multiple continuous glucose monitoring (CGM) platforms. The executive leadership team is headed by President and CEO John Sheridan, an industry veteran who previously served as the company’s COO and held senior roles at Volcano Corporation and Rapiscan Systems. Technical innovation is led by CTO Rick Carpenter, while financial operations are overseen by CFO Leigh Vosseller, who has been instrumental in the company’s scaling since its early commercial stages. The leadership also includes COO Jean-Claude “JC” Kyrillos and Chief Medical Officer Dr. Jordan Pinsker, a recognized expert in artificial pancreas technology. Founded in 2006 by Paul DiPerna, Tandem is governed by a board chaired by Rebecca Robertson and retains strong institutional support from major shareholders such as BlackRock and The Vanguard Group.